Biliary Tract Cancer clinical trials at UCSF
3 in progress, 2 open to eligible people

  • A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

    open to eligible people ages 18 years and up

    This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.

    San Francisco, California and other locations

  • Pembrolizumab and GM-CSF in Biliary Cancer

    open to eligible people ages 18 years and up

    This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at UCSF. This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.

    San Francisco, California

  • A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

    Sorry, in progress, not accepting new patients

    The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

    San Francisco, California and other locations

Last updated: